

## Press release

EQ<sub>L</sub> PHARMA

Lund, February 24<sup>th</sup>, 2025  
EQL Pharma AB (publ)  
556713-3425

# Nomination committee for the 2025 Annual General Meeting

According to the resolution of the 2024 Annual General Meeting, the Nomination Committee shall be convened by the Chairman of the Board and consist of a representative of each of the three largest shareholders in terms of the number of votes at the end of December 2024.

At the end of December, the three largest shareholders were Cadila Pharmaceuticals Ltd. and Fårö Capital AB and SEB Fonder. All have agreed to participate in the nomination committee's work.

Prior to the 2025 Annual General Meeting, the Nomination Committee consists of Christer Fåhræus (appointed by Fårö Capital AB), Rajiv I Modi (appointed by Cadila Pharmaceuticals Ltd.), and Erik Hallengren (appointed by SEB Fonder).

Shareholders who wish to submit proposals to the Nomination Committee are encouraged to send an e-mail to [info@eqlpharma.com](mailto:info@eqlpharma.com).

**For further information, please contact:**  
Axel Schörling

CEO, EQL Pharma AB (publ)  
Phone: +46 (0) 76 317 90 60  
E-mail: [axel.schorling@eqlpharma.com](mailto:axel.schorling@eqlpharma.com)  
Website: [www.eqlpharma.com](http://www.eqlpharma.com)

### EQ<sub>L</sub> Pharma AB (publ) briefly

EQ<sub>L</sub> Pharma AB specializes in developing and selling generics, ie pharmaceuticals that are medically equivalent to reference pharmaceuticals. The company currently has upwards of 40 niche generics (ie generics with limited competition apart from the reference pharmaceutical) approved in the Nordic markets. In addition to these, there is a significant pipeline of additional niche generics for launch in 2025 and beyond. The business is currently entirely focused on prescription pharmaceuticals, including hospital products, in the Nordic region and in selected European markets. EQ<sub>L</sub> Pharma AB conducts its operations in Lund and is listed on the Spotlight Stock Market. EQ<sub>L</sub> Pharma AB conducts extensive development work in collaboration with leading contract manufacturers and pharmaceutical companies in the EU and Asia, among others.